Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease

Elise L. Kessler 1,2*, Mathilde R. Rivaud 1,3, Marc A. Vos 1 and Toon A. B. van Veen 1

Abstract

Background: Cardiovascular diseases (CVDs) culminating into heart failure (HF) are major causes of death in men and women. Prevalence and manifestation, however, differ between sexes, since men mainly present with coronary artery disease (CAD) and myocardial infarction (MI), and post-menopausal women predominantly present with hypertension. These discrepancies are probably influenced by underlying genetic and molecular differences in structural remodeling pathways involved in hypertrophy, inflammation, fibrosis, and apoptosis. In general, men mainly develop eccentric forms, while women develop concentric forms of hypertrophy. Besides that, women show less inflammation, fibrosis, and apoptosis upon HF. This seems to emerge, at least partially, from the fact that the underlying pathways might be modulated by estrogen, which changes after menopause due to declining of the estrogen levels.

Conclusion: In this review, sex-dependent alterations in adverse cardiac remodeling are discussed for various CVDs. Moreover, potential therapeutic options, like estrogen treatment, are reviewed.

Keywords: Sex, Cardiovascular disease, Hypertrophy, Fibrosis, Inflammation, Apoptosis
by, e.g., Hartman et al. [6], is beyond the scope of this review.

Also metabolism, pregnancy, life-style, and environmental factors play an important contributing role on sex-differences in the most common CVDs. These influences have been reviewed extensively before [5, 7, 8]. Therefore, our review specifically aims at summarizing sex differences in the molecular remodeling mechanisms, which are particularly involved in hypertrophy, inflammation, apoptosis, and fibrosis.

**Sex differences in patients with CVD**

When generalized, prevalence of CVDs and overall mortality are independent of sex [3]. However, epidemiology and pathophysiology of CVDs often differ as has been extensively reviewed in literature and is briefly summarize below and in Table 1.

CAD and MI are more prevalent in men than in women in all age groups (43% in men versus 27% in women in the CONFIRM Long-Term Registry) and women acquire these diseases after 10 years later in life, though overall mortality has shown to be equal specifically for CAD and MI (about 50% in Writing Group 2016) [3, 9, 10]. In the CONFIRM study, women who presented with CAD were older (62.4 years versus 58.9 years in men) and suffered more from hypertension (60% versus 52% in men) [9]. After MI, women often develop HFpEF (37% versus 23% in men), whereas men mainly present with HFrEF [11]. Prevalence of hypertension keeps increasing and is the most treated risk factor for CVD and HF, leading to mainly HFpEF in women and HFrEF in men [12]. Pre-menopausal women have a lower incidence of hypertension than age-matched men (e.g., 7.3% versus 15.8% men, between 30 and 44 years of age) [13]. This difference vanishes during menopause until the age of 65, when more women present with hypertension than men. This fact is mainly thought to be caused by the influence of estrogens in females, but might also partly be explained by a genetic component as is suggested through the identification of a hypertension associated region on the Y chromosome in animals [4, 14, 15]. Reports on valvular heart diseases are contradictory, indicating that more women suffer from mitral valve disease (male:female ratio, 3:1), and depending on the different studies, either more men or women present with aortic valve disease (male:female ratio, 3:1 or 0.76:1) [3, 14].

Pulmonary hypertension causes right ventricular (RV) cardiac remodeling, with pulmonary stenosis and COPD being the two main contributors. In contrast to systemic hypertension, pulmonary hypertension is more prevalent in younger women (< 65 years) than in men (male:female ratio, 1:1.8 in the UK), but pregnancy in younger women highly contributes to these numbers. However, at older ages, the prevalence equalizes [16]. In both sexes, the disease often culminates into HFpEF, and men present with a higher mortality, despite the lower prevalence [1]. In the non-smoking group, about 80% of COPD patients are female [17].

Prevalence of the different forms of cardiomyopathies, such as DCM, HCM, and ACM is higher, average age of diagnosis is lower, and outcome is worse in men than in women (male:female ratio of DCM 1.5:1, of HCM 3:2, and of ACM 3:1) [18]. Interestingly, inherited forms of these cardiomyopathies, e.g., due to mutations in tropo-nin T (for DCM), Plakophilin-2 (for ACM) and in sarco-meric proteins (for HCM), also show a skewed incidence, suggesting that on top of the genetic predisposition, additional factors are decisive for the phenotypical expression of the disease [18].

Regardless of the cardiovascular injury, women tend to develop HFpEF, while most men develop HFrEF (e.g., 73.4% males developed HFrEF and 48% developed HFpEF in the PREVEND study [19]) as depicted in Fig. 1.

**Table 1**  
Sex differences in cardiovascular structural remodeling

|                          | Myocardial infarction | Hypertension/aortic stenosis/PO | Pulmonary hypertension/DCM | HCM/DCM | ACM |
|--------------------------|-----------------------|--------------------------------|-----------------------------|---------|-----|
| **Prevalence**           | M > F in all age groups [9, 18] | F < M pre-menopausal, F > M post-menopausal [14, 31] | F > M Pulmonary hypertension [86] F > M COPD [17] | M > F in all age groups [18] | M > F in all age groups [18] |
| **Mortality**            | M = F [3, 9]          | depending on age [3]            | M > F [1]                   | M > F in all age groups [18] | M > F in all age groups [18] |
| **Hypertrophy**          | M > F [21, 44]        | M: eccentric F: concentric [1, 14, 22, 25] | M > F [38, 39]              | M > F [69, 87] | M > F [18] |
| **Inflammation**         | M > F [48]            | M > F [34]                      | M > F [88]                  | M > F [69, 89] | Sex unmentioned [90] |
| **Fibrosis**             | M > F and M larger infarct size [44] | M > F [14, 34, 63] | M > F [67] | M > F [69] | No significant differences in fibro-fatty replacement [71] |
| **Apoptosis**            | M > F and M larger infarct size [62] | M > F [64]                      | M > F [67] | M > F [69] | M > F in iPS cells [72] |

Abbreviations: F = female; M = male; ACM = arrhythmogenic cardiomyopathy; COPD = chronic obstructive pulmonary disease; DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; PO = pressure overload
Whether women developing HFrEF or men developing HFrEF show the same characteristics of cardiac remodeling as their counterparts is currently still under investigation (indicated in with a question mark).

Sex differences in molecular pathways of adverse cardiac remodeling
CVDs trigger adverse cardiac remodeling, which is manifested by hypertrophy, inflammation, fibrosis, and apoptosis, eventually leading to HF. Many of these processes are often sex-specific (see Table 1) and influenced by sex-hormone levels of estrogen, testosterone, or progesterone [20]. Obviously, men and women are on different hormonal schedules, and although the hormonal shifts during a woman’s life are more frequent and dramatic than in a man’s life, it is thought that the effects of sex-hormones, in particular estrogen, during the pre-menopausal period are able to delay the appearance of CVDs in women [15]. This is supported by the observation that women with irregular hormone cycles and an early menopause have an elevated risk of HF [20].

In the following sections, we will discuss the mentioned mechanisms and processes triggering adverse cardiac remodeling in the light of sex-specific differences.

**Hypertrophy**
The development and manifestation of cardiac hypertrophy differs between the sexes. Generally, in women, LV remodeling due to MI or aortic stenosis/hypertension is oriented towards concentric hypertrophy leading to diastolic dysfunction (Fig. 1 pink lines). In men, eccentric hypertrophy with chamber dilatation is the most common, eventually leading to systolic dysfunction (Fig. 1 blue lines) [1, 21, 22]. Next to that, the amount of viable cardiomyocytes decreases in the healthy aging male heart more extensively than in the female heart, making it at baseline already more susceptible to stress and hypertrophy [23]. As mentioned, this effect in females is thought to be, at least in part, due to estrogens and estrogen receptor (ER) signaling, which is especially mediated by the estrogen receptor beta (ER-β) [24]. Studies in animal models support this. Mice lacking...
the ER-β develop hypertrophy faster, and females with aortic stenosis show a more extensive upregulation of ER-β, while ER-α is upregulated to the same extent in both sexes [25, 26]. Estrogen-treated ovariectomized (OVX) female mice show a slower development of LV hypertrophy compared to untreated OVX animals [27]. In patients, estrogen is associated with a better RV systolic function, and androgens, such as testosterone, with an increased RV mass and volume, as is seen during hypertrophy [28]. Moreover, estrogen is known to modulate natriuretic peptides, e.g., pro-brain-type natriuretic peptide (BNP) and activates angiogenesis, which supports the hypertrophic heart in its elevated oxygen demand [29]. Estrogen has also been shown to temper hypertrophic remodeling through CaMKII inhibition, which adds to the preserved EF in pre-menopausal women [30].

Pre-menopausal women have a lower incidence of hypertension than age-matched men as mentioned earlier. This is in line with observations that estrogen can modulate β-adrenergic signaling and may cause vasodilation by increasing endothelial nitric oxide synthase (eNOS) [31]. LV pressure overload leads in general to activation of the neuro-hormonal axis and to an increase of the sympathetic drive. In young men, peripheral resistance is proportional to sympathetic drive, though not in young women. Post-menopausal peripheral resistance increases with sympathetic drive [32]. This is probably due to the decrease of estrogen, since baroreflex sensitivity is modulated by estrogens [33]. Because of that, post-menopausal women have a higher prevalence of hypertension and pulmonary hypertension. In addition, men with aortic stenosis show a more robust upregulation of genes related to the renin–angiotensin–aldosterone system (RAAS), whereas women are able to repress the gene encoding for angiotensinogen [34]. Transverse aortic constriction (TAC), mimicking aortic stenosis in mice and rats, shows in the majority of studies that female animals develop HF later than males, accompanied with a less dilated phenotype [35].

Although estrogen is known for its vasodilator properties, pulmonary hypertension is more prevalent in younger women, and the role of estrogens and testosterone in pulmonary hypertension remains controversial. After hypoxia-induced pulmonary artery hypertension in mice with overexpressed serotonin transporters, OVX leads to a reduced RV hypertrophy, whereas estrogen therapy (ET) re-established the hypertension phenotype [36, 37]. In contrast, in rats with pulmonary hypertension, experimentally induced by, e.g., monocrotaline or bleomycin, estrogen has been reported to be beneficial against RV hypertrophy, inflammation, and fibrosis, and females show a less severe phenotype than males [38]. Besides that, these different outcomes might be related to differences in the type of rodent and the method used to induce hypertension; in numerous studies, female animals show less pulmonary hypertension than male animals as reviewed in Mair et al. [39]. However, the same investigators suggest that men are probably more protected from pulmonary hypertension due to the fact that the vasodilatory effects of testosterone are more important in the pulmonary vasculature than that of estrogens [39].

HCM presents by definition with concentric and DCM with eccentric hypertrophy. Both disorders are more prevalent in men as discussed before. Also in mice, females seem to develop less DCM and HCM than males, and later in life upon end-stage HF induced by chronic LV pressure overload [18]. ACM leads to predominantly RV dilatation in humans and mice (e.g., upon Plakophilin-2 knockout) [40], but also biventricular phenotypes are known [41]. In ACM, dilatation may be caused by increased stretch of the cardiac walls and be more visible in the right ventricle, since this wall is significantly thinner [42]. In men, this effect is often more pronounced, which might be due to a higher intrinsic sympathetic drive and activity in young men and male children [43].

Although studies in animals highlight potential mechanisms of cardiovascular remodeling mediated by sex-hormones, these models often make use of one sex-hormone at a time and are therefore not optimal representations of the fine balance between different sex-hormones under physiological conditions. Extrapolations to the human condition should therefore be considered with care.

**Inflammation**

Inflammatory pathways contribute to the progression of adverse remodeling and are activated upon cardiac injury. As mentioned before, the Y chromosome contains several genes involved in, e.g., macrophage activation [4]. Higher numbers of neutrophils and macrophages in males lead to an increased extent of inflammation, and together with a reportedly higher activity of matrix metalloproteinases (MMPs), this can cause premature breakdown of collagen and thereby cardiac rupture and slowed healing after injury or during HF [44].

The most common inflammatory pathways triggering secretion of cytokines and chemokines and subsequently the attraction of inflammatory cells like dendritic cells and macrophages are depicted in Fig. 2 and discussed in the following paragraphs.

**The JAK-STAT pathway** Binding of a ligand to the interferon (IFN) receptor leads to activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, causing translocation of a STAT
dimer to the nucleus (Fig. 2, purple pathway). A study showed that in women undergoing LV adverse remodeling due to pressure overload, genes of the JAK-STAT pathway are significantly downregulated [34]. Mechanical strain upon hemodynamic stress (such as in TAC animal models) induces production of the cytokine interleukin-6 (IL-6), activating the JAK-STAT pathway, and also the toll-like receptor (TLR) pathway (Fig. 2, green pathway) [45]. Female mice lacking the ER-β have significantly increased activation of inflammatory signals, such as IL-6, and presence of ER-β seems to prevent cardiac inflammation and fibrosis in mice upon TAC [25, 46].

The toll-like receptor pathway The inflammatory TLR pathway activation is associated with adverse cardiac remodeling, arrhythmias, and HF [47]. Binding of a ligand to a TLR (either in an endosome (Fig. 2, left green pathway) or on the cell membrane (Fig. 2, green pathway)) leads to either translocation of IRF3 or AP1 to the nucleus, or degradation of the inhibitor of NFκB (IκB) and consequently transport of NFκB to the nucleus. In women, the TLR pathways are to a lesser extent activated than in men, and male patients show increased expression of various inflammatory proteins upon LV remodeling (e.g., chemokine receptor-1, IL-33, and TLR7) [34]. In animals with experimentally induced hypertension and MI, TLR expression is increased in males, while knockout of TLRs (e.g., TLR4 and TLR2) improves cardiac function more in males than in females after MI [48–51]. Interestingly, ER-α can act as a transcription factor, which can inhibit expression of NFκB [52].
Crosstalk between different remodeling mechanisms is noticed since hypertrophy can interact with inflammatory signaling, where CaMKII (which is prominently activated during adverse remodeling) can directly phosphorylate components of the TLR pathway, thereby promoting cardiac inflammation (Fig. 2, black arrow) [53]. As mentioned above, estrogens can interact with CaMKII and members of the TLR pathway, therefore playing an important part in this interaction. In the future, therapeutic interference with these pathways, as exemplified by TLR blockers, should therefore take the sex of the patient and his/her hormone levels into account.

**The Wnt pathway** During inflammation, the Wnt pathway (Fig. 2, gray pathway) is activated and known to regulate T cell development, dendritic cell, and leukocyte maturation [54]. Activation of the Wnt pathway leads to degradation of the GSK3-β complex resulting in distortion of catenins from the membrane and translocation to the nucleus. Men with aortic stenosis show a larger upregulation of the Wnt pathway than women [34]. Crosstalk between the Wnt/β-catenin and the TLR pathway has been reported, where depletion of β-catenin leads to increased levels of TLR4 [54]. In ACM patients, mutation of γ-catenin (also known as Plakoglobin) or β-catenin causes weakening of intercellular junctions, probably leading to detachment of cardiac cells. This causes cell death and necrosis, which has been associated with inflammation and eventually fibrosis formation, although sex differences in this regard have not been investigated [55]. Not only interactions between GSK3 and ER-α, but also androgen receptors have been reviewed in detail [56], and this should be taken into account when investigating for example GSK3-β blockers. Furthermore, Wnt signaling is involved in a plethora of (developmental) processes, making it a difficult target for therapeutic interventions.

**The TNF pathway** Binding to the tumor necrosis factor (TNF) receptor activates TRADD (Fig. 2, red pathway), which in turn either activates FADD and the apoptotic caspase pathway or TRAF2, which leads to cross activation of the TLR (green pathway) and TGF-β and bone morphogenic protein (BMP) pathways (Fig. 2, blue pathway). Also upon MI, the apoptotic pathway is activated by caspase-11 that in turn can activate caspase-1. The latter is able to induce interleukin (e.g., IL-1α, IL-6) and TNF-α production, and their secretion causes activation of more inflammatory cells and pathways, such as the TLR and MEKK pathway [57]. Estrogen has been shown to inhibit the synthesis of TNF-α, thereby hampering the activation of inflammatory cells and fibroblasts [58]. This suggests that in women, the TNF pathway is less active compared to men and therefore the development/progression of CVDs might be slowed. Repressing the TNF pathway therapeutically might therefore have a greater benefit in men and post-menopausal women than pre-menopausal women.

**The TGF-β and BMP pathway** Invading inflammatory cells, such as macrophages, express the TGF-β receptor, which is able to mediate the inflammatory response [59]. Activation of the TGF-β or BMP receptor leads to SMAD complex formation, activation of Ras and the mitogen-activated protein kinase pathway, or activation of PI3K (Fig. 2, blue pathways). This eventually results in epithelial to mesenchymal transition or activation of the mTOR pathway causing changes in cell cycle and proliferation. Women show lower expression of TGF-β and a lower inflammatory response [34] probably since ER-β binding by estrogen on fibroblasts has been shown to block TGF-β and AngII stimulation [46]. In addition, TGF-β is highly pro-fibrotic and macrophages play a role in transition of fibroblasts to myofibroblasts; the latter being more pro-fibrotic in their activity [59]. This illustrates the tight connection between inflammatory and fibrotic responses in cardiac remodeling, logically leading to less of both in women, or at least a delay in response when compared to men.

Concluding, all cardiac inflammatory pathways can be modulated by estrogen and therefore, sex differences should be taken into account when conducting research on and/or testing therapeutic interventions on CVDs.

**Fibrosis and apoptosis**

During all forms of CVDs and HF, and in both sexes, cardiac fibroblasts secrete excessive amounts of collagen into the extracellular matrix. While collagen genes are upregulated in all kinds of human CVDs and rodent disease models, Metalloproteinases (MMPs) are often downregulated or unchanged, and Tissue Inhibitors of MMPs (TIMPs) are either upregulated or also unchanged, as thoroughly reviewed in Fan et al [60]. Besides, although different CVDs result in different patterns of fibrosis, its formation and deposition appears later in the process of remodeling in women as compared to men [34].

Apoptosis is the programmed cell death following, e.g., cardiac injury, and in general, female failing hearts show lower rates of apoptosis and necrosis than males. This could, on the one hand, be due to the presence of apoptosis-related genes on the Y chromosome, or on the other hand, although not completely understood, due to the role of estrogen and ERs [4].

After MI in mouse models, mostly compact fibrosis is found due to massive apoptosis and necrosis in the infarcted area, which is more extensive and results in more...
collagen content in male mice compared to females [61]. This is further confirmed in humans, where apoptosis after MI is more prevalent in men compared to women [62]. After pressure overload, female rodents present with lower levels of apoptotic proteins, such as caspase 3 and 9, and ER-β signaling attenuates apoptosis and seems to prevent cardiac fibrosis upon chronic pressure overload and in HF [25, 63, 64]. In O VX rats, estrogen therapy is able to reduce collagen content and MMP/TIMP balance upon LV pressure overload and apoptotic therapy is able to reduce collagen content and MMP/TIMP balance upon LV pressure overload and apoptotic content [64, 65]. In addition, as already explained, females show lower levels of TGF-β and angiotensinogen, both involved in synthesis and deposition of fibrosis [34]. Male patients undergoing aortic valve surgery, on the other hand, display increased levels of collagens I and III, and MMP expression as compared to female patients [66]. In male HFpEF patients, also expression of TIMP-2 appeared to be increased, as compared to females [34]. Pulmonary hypertension leads to RV fibrosis and apoptosis in both sexes [67]. Reports on the role of sex-hormones in pulmonary hypertension are contradictory: since prevalence is higher in females, one would suggest a protective role for, e.g., testosterone. However, castrated rats with pulmonary hypertension showed the opposite since decreased RV fibrosis was observed while administration of testosterone lead to an increase in collagen content [68].

Women with DCM have less fibrosis and apoptosis, and show a more reversible type of HF in clinics [69]. In DCM patients with lamin A/C mutations, nuclear accumulation of androgens such as testosterone has been found, and castrated mice carrying the same mutations showed improved cardiac function and less cell death and fibrosis [70]. Structural sex-based differences in the clinical manifestation of ACM, such as the disease-characteristic fibro-fatty replacement and apoptosis, have not been reported [71], probably since detection is predominantly based on MRI which allows only the detection of larger areas of fibrosis. However, in a recent study, testosterone worsened and estradiol improved the degree of cardiac apoptosis and lipogenesis in an ACM model of induced pluripotent stem cells [72]. Moreover, lipid metabolism seems to be associated with loci on the sex chromosomes, possibly leading to sex-specific differences in fibro-fatty replacement [4].

Apoptosis and fibrosis in the myocardium cause structural abnormalities and inhomogeneity of the syncytium, which is an important factor that affects efficiency of contractility and predisposes to arrhythmogenesis [73]. Therefore, delayed deposition of fibrosis and apoptosis in female hearts as compared to males might postpone the appearance of such cardiac dysfunctions and should be targeted in future research in a sex-specific manner.

### Sex differences in therapeutic interventions

Pharmacological interventions for CVDs and HF include prescription of statins, neuro-hormonal blockage by, e.g., angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers and β-blockers, and instrumentation via, e.g., an implantable cardiac defibrillator (ICD) in order to prevent sudden death caused by arrhythmic events. In general, except for diuretics, most drugs are more often prescribed in men than in women, even after adjusting for age and mortality. Often absorption, distribution, metabolism, and clearance differ between sexes and sex-specific differences have been reviewed in, for instance Tamargo et al. [74], and are shortly summarized in Table 2. Unfortunately, current guidelines are not considering these differences and therapeutic interferences like neuro-hormonal blockage are to a lesser extent beneficial in patients with HFpEF and therefore, in general, less effective in women than in men [3]. Moreover, women have a lower distribution volume for medications, such as β-blockers, related to differences in body dimensions and fat distribution, and often show a lower clearance rate [75]. Prescription of drugs varies between sexes, where statins, for example are more likely prescribed to men than women (64.8% in men versus 57.6% in women). Furthermore, of all ICD implantations, only 17–26% are performed in women [76–78]. The latter most likely can be explained by the fact that guidelines for ICD therapy (LVEF < 35%) are based on the results of clinical trials, where men are overrepresented.

Pharmacological treatment for pulmonary hypertension mainly includes calcium channel blockers, whose

| Table 2 | Sex differences in therapeutic options for CVDs |
| --- | --- |
| Therapeutic option | Effect |
| Statins | M = F [78], but F higher risk of adverse drug reaction |
| ACE inhibitors | M = F [74] |
| Angiotensin receptor blockers and β-blockers | M = F, but F slower clearance, lower volume of distribution, and less sensitive [74] |
| ICD | M = F [76, 77] |
| Calcium channel blockers | F faster clearance of, e.g., verapamil and nifedipine, but faster reduction of blood pressure [74] |

Abbreviations: F = female; M = male; ACE = angiotensin-converting enzyme; ICD = implantable cardiac defibrillator
mode of action can be increased in women due to higher bioavailability [16, 74].

Therapy for ACM aims at preventing arrhythmias and reducing the rate of SCD with, e.g., exercise restrictions and ICD therapy [41]. Since ICD therapy in ACM is often used as primary prophylaxis, sex-biased outcomes are not that prominent.

Since many differences exist between the response and therapies, and therefore their efficiency between women and men, it is surprising that there are no sex-specific guidelines to treat CVDs and HF. Most of the therapeutic options are driven by the manifestation of CVDs in men, while they are also the primary cause of death in women [1]. Future sex-specific therapeutic options should therefore focus on the underlying differences in cardiac remodeling, but one should also keep in mind that often the primary injury seems to be already different between sexes. This is, e.g., the case in CAD, where women show more often microvascular and men macrovascular dysfunction [10]. Furthermore, biomarker reference intervals for these diseases have not historically been established for men and women separately, which may partially contribute to the gaps in underlying diagnosis.

This together illustrates that sometimes a different treatment-regimen will be needed for men and women.

Estrogen therapy (ET) has been investigated as a potential treatment for CVDs in post-menopausal women as extensively reviewed in Miller and Harman [79]. In rodents with chronic pressure overload, ET seems to increase EF and reduce fibrosis formation [80]. However, controversial results in clinical trials using ET show either improvement of contractile performance upon, e.g., hypertension or an actual increase in the risk of stroke, MI, and pulmonary embolism [81]. The effect might be dependent on the type of estrogen administered (e.g., differently dosed 17-β estradiol (1 or 2 mg), estradiol valerate, conjugated equine estrogen, or combined therapies), the way of administration (orally or non-orally), and the timing/frequency. Besides that, positive effects of ET are often only seen in clinical trials, if estrogen is administered within 1 year after menopause suggesting that it is not possible to reverse some permanent alterations during disease progression (e.g., fibrosis or accumulation of atherosclerotic plaques) [82].

Furthermore, in “extreme patients,” such as individuals with congenital Turner syndrome, the effect of lack of estrogen can be highlighted. Women with Turner syndrome lack one X chromosome partially or fully and often suffer from premature ovarian failure leading to estrogen deficiency or even depletion [83]. These women often present with hypertension are at risk for various cardiac diseases and have a 3-fold increased mortality. Hormone replacement therapy and ET is a standard therapy that is already initiated early in life. ET in the affected women does not only normalize, e.g., uterine size, but was also shown to improve blood pressure and, at a high dose, increased the cardiac intima media thickness as intensively reviewed in Cintron et al. [83].

In line with that, women with congenital Kallmann syndrome are characterized by hypogonadotropic hypogonadism and anosmia. Moreover, they often suffer from congenital heart diseases. ET is also used in these cases already early in life to induce secondary sex characteristics, but less is known about its potential role in cardioprotection [84].

Conclusions and future perspectives
Although sex-specific discrepancies are seen in almost all CVDs, appropriate diagnosis and consequent therapies are not well established. This is not only partly due to severe underrepresentation of women in clinical trials (young women were even banned from clinical trials by the FDA from 1977 to 1993) [85], but also caused by the lack of knowledge on molecular disparities between sexes with regard to cardiac remodeling pathways for hypertrophy, inflammation, fibrosis, and apoptosis. In this review, we summarized the knowledge on sex-dependent differences in these pathways and the involvement of sex-hormones, especially estrogen. Overall, women show less fibrosis, hypertrophy, and inflammation upon CVDs than men, often preserving their EF. This leads to an onset of a most often different phenotype of HF later in life, but on the other hand prevents women from receiving the appropriate timely treatment, since the absence of a proper HF diagnosis means that no treatment will be provided. This increases the risk of sudden cardiac death in females. Therefore, also women with HFpEF should be treated or at least be monitored to reduce mortality in this group.

Moreover, women seem to seek less cardiac health care, treatment (such as an ICD) is often less well perceived and induces more psychological discomfort (depression and stress) than in men, and men are more often heart donors and receivers [14, 35]. Partially, this could rely on the fact that different cardiac symptoms are experienced by women and men, which could hamper the recognition in women that they actually are experiencing, e.g., an MI. These facts demonstrate that sex-specific differences in the underlying mechanisms of structural remodeling indeed lead to differences in CVDs and health care and should be more thoroughly investigated to advance and specify treatment.

Abbreviations
ACE: Angiotensin-converting enzyme; ACM: Arrhythmogenic cardiomyopathy; BNP: Pro-brain-type natriuretic peptide; CAD: Coronary artery disease; CaMK II: Calmodulin kinase 2; COPD: Chronic obstructive pulmonary disease; CVD: Cardiovascular disease; DCM: Dilated...
cardiomyopathy; ECM: Extra cellular matrix; eNOS: Endothelial nitric oxide synthase; ER: Estrogen receptor; ET: Endothelin therapy; ET-1: Endothelin-1; HCM: Hypertrophic cardiomyopathy; HF: Heart failure; HFrEF: Heart failure with moderate LVEF; HFpEF: Heart failure with preserved LVEF; ICD: Implantable cardiac defibrillator; IFN-γ: Interferon-γ; IL: Interleukin; IJK: Janus kinase/signal transducer and activator of transcription; LV: Left ventricle; LVEF: Left ventricular ejection fraction; MEKK: Mitogen-activated protein kinase kinase; MI: Myocardial infarction; MMP: Matrix metalloproteinase; MR: Magnetic resonance imaging; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; O VX: Ovariectomized; PLN: Phospholamban; RAAS: Renin–angiotensin–aldosterone system; RV: Right ventricle; SCD: Sudden cardiac death; TAC: Transverse aortic constriction; TG F-β: Transforming growth factor-β; TIMP: Tissue inhibitor of MMP; TLR: Toll-like receptor.

Acknowledgements
None.

Funding
This work was supported by the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences (CVON-PREDICT 2012-10).

Availability of data and materials
Not applicable.

Authors' contributions
ELK made substantial contributions to conception and design, and drafted the manuscript. MRR was involved in conception and design, and drafting the manuscript or revising it critically for important intellectual content. MAW was involved in revising the manuscript critically for important intellectual content. TABV made substantial contributions to conception and design of the manuscript and was involved in drafting the manuscript or revising it critically for important intellectual content. All authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors give consent for publication for all content.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Medical Physiology, Division of Heart and Lungs, University Medical Center, Utrecht, Utrecht University, Y alea1aan 50, 3584CM Utrecht, The Netherlands. 2Department of Experimental Cardiology, Division of Heart and Lungs, University Medical Center, Utrecht, Utrecht University, P.O.Box B5500, Heidelberglaan 100, Utrecht 3584CT, The Netherlands. 3Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, Amsterdam, The Netherlands.

Received: 11 July 2018 Accepted: 24 January 2019
Published online: 04 February 2019

References
1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(21):2129–200.
2. Bleumink GS, Knetisch AM, Sturkenboom MCJM, Struys MMJ, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure—the Rotterdam study. Eur Heart J. 2004;25(18):1614–9.
3. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–360.
4. Winham SJ, de.Andrade M, Miller VM. Genetics of cardiovascular disease: importance of sex and ethnicity. Atherosclerosis. 2014;241(1):219–28.
5. Regitz-Zagrosek V, Karagias G. Mechanistic pathways of sex differences in cardiovascular disease. Physiol Rev. 2017;97(1):1–37.
6. Hartman RGG, Huisman SE, Den Ruijter HM. Sex differences in cardiovascular epigenetics—a systematic review. Biol Sex Differ. 2018;9:19.
7. Chella Krishnan K, Mehrabian M, Luisi AJ. Sex differences in metabolism and cardiometabolic disorders. Curr Opin Lipidol. 2018;29(3):404–10.
8. Appelman Y, van Rijn BB, ten Haaf ME, Boersma E, Peters SE. Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis. 2014;241(1):211–8.
9. Schluman-Marcus J, Hartaig BO, Gransar H, Lin F, Valenti V, Cho I, et al. Sex-specific associations between coronary artery plaque extent and risk of major adverse cardiovascular events the CONFIRM long-term registry. JACC Cardiovascular Imaging. 2016;9(4):364–72.
10. Maas AH, Appelman YEA. Gender differences in coronary heart disease. Neth Heart J. 2010;18(12):598–603.
11. Hellermann JP, Jacobsen SJ, Reeder GS, Lopez-Jimenez F, Weston SA, Roger VL. Heart failure after myocardial infarction: prevalence of preserved left ventricular systolic function in the community. Am Heart J. 2003;145(4):742–8.
12. Lam CSP, Donal E, Klaiger-Kraemer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur Heart Fail. 2011;13(1):18–28.
13. Neuhauer H, Thamm M, Ellert U. Blood pressure in Germany 2008-2011: results of the German Health Interview and Examination Survey for Adults (DEGISI). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(6–8):795–801.
14. Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, Franconi F, Gerds T, Frist-Ludwig A, et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37(1):24–34.
15. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–11.
16. Opitz C, Rosenkranz S, Ghofrani HA, Erpelding J, Olschewski H, et al. ESC guidelines 2015 pulmonary hypertension: diagnosis and treatment. Dtsch Med Wochenschr. 2016;141(26):1764–9.
17. Ayal S, Diaz-Guzman E, Mannino DM, COPD and gender differences: an update. Transl Res. 2013;162(4):208–18.
18. Meyer S, van der Meer P, van Tintelen JP, van den Berg MP. Sex differences in cardiomyopathies. Eur J Heart Fail. 2014;16(3):238–47.
19. Brouwers FP, De Boer RA, Van Der Harst P, Voors AA, Gansevoort RT, Bakker SJ, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of the PREVEND. Eur Heart J. 2013;34(19):1424–31.
20. Appiah D, Schreiner PJ, Dernarow EA, Loehr LR, Chang PP, Folsom AR. Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis. J Am Heart Assoc. 2016;5(8):e003769.
21. Crabbde DL, Diapla K, Ambabi S, Zeferedis A, Gaughan JP, Houser SR, et al. Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol. 2003;41(2):300–6.
22. Aurigenva GA, Gass HH. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiol. 1995;86(4):310–7.
23. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res. 1991; 68(6):1560–8.
24. Skudvahl M, Steeneberg C, Clark J, Myers P, Demianenko T, Mao L, et al. Estrogen receptor-β mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Circ Physiol. 2005;288(2):469–76.
25. Karagias G, Fleignier D, Gustafsson J-A, Regitz-Zagrosek V. Role of the estrogen/estrogen-receptor-beta axis in the genomic response to pressure overload-induced hypertrophy. Physiol Genomics. 2011;43(8):436–48.
26. Mahmoodzadeh S, Eder S, Nordmeyer J, Ehler E, Huber O, Martus P, et al. Estrogen receptor alpha up-regulation and redistribution in human heart failure. FASEB J. 2006;20(7):926–34.
27. Van Eickels M, Grohé C, Cleutjens JPM, Janssen BI, Wellens HJJ, Doevendans PA. 17β-estradiol attenuates the development of pressure-overload hypertension. Circulation. 2001;104(11):1419–23.
28. Ventetoulo CE, Quyang P, Bluemcke DA, Tandrit H, Barr RG, Baggiella E, et al. Sex hormones are associated with right ventricular structure and function: the MESA-right ventricle study. Am J Respir Crit Care Med. 2011;183(5):659–67.

29. Kurosaki De Bold ML. Estrogen, natriuretic peptides and the renin-angiotensin system. Cardiovasc Res. 1999;41(3):524–31.

30. Pedram A, Razandi M, Narayanay R, Dalton JT, McKinsey TA, Levin ER. Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell. 2013;24(24):3805–18.

31. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol. 2002;90(1A):3F–6F.

32. Shoemaker JK, Hogeman CS, Khan M, Kimmerly DS, Sinoway LI. Gender differences in responses to inotropic interventions in mice. J Appl Physiol Heart Circ Physiol. 2001;81(5):2028–35.

33. Barnes JN, Matzek LJ, Charkoudian N, Jouyn MJ, Curry TB, Hart EC. Association of cardiac baroreflex sensitivity with blood pressure transients: influence of sex and menopausal status. Front Physiol. 2012;13:187.

34. Kararigas G, Dworatzek E, Petrov G, Summer H, Schulze TM, Baczko I, et al. Sodium current deficit and arrhythmogenesis in a murine model of estrogen-deficient females. Am J Physiol Heart Circ Physiol. 2001;281(5):H190–7.

35. Regitz-Zagrosek V, Seeland U. Sex and gender differences in myocardial hypertrophy and heart failure. Wien Med Wochenchr. 2011;161(5–6):109–16.

36. White K, Dempsey J, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17β-oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res. 2011;90(2):373–82.

37. English KM, James RD, Jones TH, Morice AH, Channer KS. Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res. 2001;33(11):645–52.

38. Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vasconol. 2009;51(2–3):190–7.

39. Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol. 2014;171(3):567–79.

40. Cerrado D, Wichter T, Link MS, Hauer R, Marchlinski FE, Anastasakis A, et al. Regression of myocardial hypertrophy after aortic valve replacement: a clue to their different clinical course? Heart. 2005;91(1):99–101.

41. Pedram A, Razandi M, Narayanay R, Levin ER. Estrogen receptor beta signals to inhibition of cardiac fibrosis. Mol Cell Endocrinol. 2016;434:57–68.

42. Dent MR, Tappa PS, Dhalla NS. Gender differences in apopotic signaling in heart failure due to volume overload. Apoptosis. 2010;15(4):499–510.

43. Soler-Vila A, Komajda M. Sex and gender differences in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical manifestations, electrophysiological properties, substrate characteristics, and prognosis of radiofrequency catheter ablation. Int J Cardiol. 2017;227:930–3.

44. Akdis D, Saguner AM, Shah K, Wei C, Medeiros-Domingo A, Von Eckardstein A, et al. Gender differences in cardiomyocyte function and remodeling through enhanced inflammatory response. Hypertension. 2011;57(2):208–15.

45. Liu X, Yao M, Li N, Wang C, Zheng Y, Cao X. CaMKII promotes TLR-triggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Blood. 2008;112(13):4961–70.

46. Ma B, Hottiger MO. Crosstalk between wnt/b-catenin and NF-kB signaling pathway during inflammation. Front Immunol. 2016;7:378.

47. Zhang X, Jackson EK, Zhu H, Petrusevska G. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vasc Pharmacol. 2001;33(11):645–52.

48. Tofovic SP, Zhang X, Jackson EK, Zhu H, Petrusevska G. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vasconol. 2009;51(2–3):190–7.

49. Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol. 2014;171(3):567–79.

50. Cassells J, White K, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17β-oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res. 2011;90(2):373–82.

51. Fani D, Takaawa A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012;5(1):15.

52. Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol. 2014;171(3):567–79.

53. Cerrado D, Wichter T, Link MS, Hauer R, Marchlinski FE, Anastasakis A, et al. Regression of myocardial hypertrophy after aortic valve replacement: a clue to their different clinical course? Heart. 2005;91(1):99–101.

54. Pedram A, Razandi M, Narayanay R, Levin ER. Estrogen receptor beta signals to inhibition of cardiac fibrosis. Mol Cell Endocrinol. 2016;434:57–68.

55. Dent MR, Tappa PS, Dhalla NS. Gender differences in apoptotic signaling in heart failure due to volume overload. Apoptosis. 2010;15(4):499–510.

56. Soler-Vila A, Komajda M. Sex and gender differences in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical manifestations, electrophysiological properties, substrate characteristics, and prognosis of radiofrequency catheter ablation. Int J Cardiol. 2017;227:930–3.
76. Amit G, Süleiman M, Konstantino Y, Luria D, Kazatsker M, Chetboun I, et al. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the nationwide Israeli-ICD registry. Europace. 2014;16(8):1175–80.

77. Varma N, Mittal S, Pillinger JB, Snell J, Dalal N, Piccini JP. Survival in women versus men following implantation of pacemakers, defibrillators, and cardiac resynchronization therapy devices in a large, nationwide cohort. J Am Heart Assoc. 2017;6(5):e005031.

78. Venkatesh S, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, et al. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015;115(1):21–6.

79. Miller V, Harman SM. An update on hormone therapy in postmenopausal women: mini-review for the basic scientist. Am J Physiol Heart Circ Physiol. 2017;313(5):H1013–21.

80. Iorga A, Li J, Sharma S, Umar S, Bopassa JC, Nadadur RD, et al. Rescue of pressure overload-induced heart failure by estrogen therapy. J Am Heart Assoc. 2016;5(1):1–12.

81. Boardman HMP, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst Rev. 2015;10(3):CD002228.

82. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women—a meta-analysis. J Gen Intern Med. 2006;21(9):1036–6.

83. Cintron D, Rodriguez-Gutierrez R, Serrano V, Latortue-Albino P, Envin PJ, Murad MH. Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with Turner syndrome: a systematic review and meta-analysis. Endocrine. 2017;55(2):366–75.

84. Meczekalski B, Podfigurna-Stopa A, Smolarczyk K, Genazzani AR. Kallmann syndrome in women: from genes to diagnosis and treatment. Gynecol Endocrinol. 2013;29(4):296–300.

85. Liu KA, Dipietro Mager NA. Women’s involvement in clinical trials: historical perspective and future implications. Pharm Pract. 2016;14(1):708.

86. Olsson KM, Channick R. Pregnancy in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(341):1–7.

87. Patten RD. Models of gender differences in cardiovascular disease. Drug Discov Today Dis Models. 2007;4(4):227–32.

88. Austin ED, Lahm T, West J, Tofovic SP, Johansen AK, Maclean MR, et al. Gender, sex hormones and pulmonary hypertension. Pulm Circ. 2013;3(2):294–314.

89. Sheppard R, Bedi M, Kubota T, Semigran MJ, Dec W, Holubkov R, et al. Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol. 2005;46(6):1036–42.

90. Camplin ME, Verberne HJ, Hardtjeszenka M, De Groot EAA, Van Moerkerken AF, Van Eck-Smit BLF, et al. Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Nucl Med Mol Imaging. 2010;37(11):2079–85.